Cargando…

The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer

SIMPLE SUMMARY: The treatment of advanced non-small cell lung cancer (NSCLC) after the age of 65 raises age-related problems as the elderly are often affected by other diseases, not infrequently chronic, take drugs that may interfere with anti-cancer treatment and are sometimes unable to fully under...

Descripción completa

Detalles Bibliográficos
Autores principales: Spagnuolo, Alessia, Gridelli, Cesare
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136482/
https://www.ncbi.nlm.nih.gov/pubmed/37190247
http://dx.doi.org/10.3390/cancers15082319
_version_ 1785032228781162496
author Spagnuolo, Alessia
Gridelli, Cesare
author_facet Spagnuolo, Alessia
Gridelli, Cesare
author_sort Spagnuolo, Alessia
collection PubMed
description SIMPLE SUMMARY: The treatment of advanced non-small cell lung cancer (NSCLC) after the age of 65 raises age-related problems as the elderly are often affected by other diseases, not infrequently chronic, take drugs that may interfere with anti-cancer treatment and are sometimes unable to fully understand relevant information. Moreover, they do not represent the ideal patient for enrolment in clinical trials, even with immunotherapy, which is now the choice therapy for the first-line treatment of NSCLC. With a view to offering more time to patients with metastatic NSCLC, the issues of quality of life and appropriateness of oncological care in the elderly are of primary importance. This review stresses the need to find a common approach to lung cancer management in a steadily aging society and describes the main currently available data on the use of immune checkpoint inhibitors in older patients with advanced NSCLC, confirming the necessity for reliable biomarkers that predict immune response to assess which patients benefit from which type of immunotherapy. ABSTRACT: Immune checkpoint inhibitors have changed the history of NSCLC treatment by becoming, alone or in combination with platinum-based chemotherapy, a mainstay of first-line therapy for advanced NSCLC. This increasingly dictates the identification of predictive biomarkers of response that can guide patient selection, in order to rationalize and personalize therapies, particularly in elderly patients. Immunotherapy in these patients raises questions of efficacy and tolerability related to aging, which is accompanied by a progressive decline in various body functions. Physical, biological and psychological changes contribute to individual validity status and, preferably, ‘fit’ patients are generally enrolled in clinical trials. In elderly patients, especially frail and complex patients with more than one chronic disease, data are poor and specific prospective studies are needed. This review reports the main available results on the use of immune checkpoint inhibitors in older patients with advanced NSCLC, in terms of efficacy and toxicity, and aims to highlight the need to better predict which patients might benefit from immunotherapy agents by probing knowledge and integrating information on immune system changes and age-related physiopathological modifications.
format Online
Article
Text
id pubmed-10136482
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101364822023-04-28 The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer Spagnuolo, Alessia Gridelli, Cesare Cancers (Basel) Review SIMPLE SUMMARY: The treatment of advanced non-small cell lung cancer (NSCLC) after the age of 65 raises age-related problems as the elderly are often affected by other diseases, not infrequently chronic, take drugs that may interfere with anti-cancer treatment and are sometimes unable to fully understand relevant information. Moreover, they do not represent the ideal patient for enrolment in clinical trials, even with immunotherapy, which is now the choice therapy for the first-line treatment of NSCLC. With a view to offering more time to patients with metastatic NSCLC, the issues of quality of life and appropriateness of oncological care in the elderly are of primary importance. This review stresses the need to find a common approach to lung cancer management in a steadily aging society and describes the main currently available data on the use of immune checkpoint inhibitors in older patients with advanced NSCLC, confirming the necessity for reliable biomarkers that predict immune response to assess which patients benefit from which type of immunotherapy. ABSTRACT: Immune checkpoint inhibitors have changed the history of NSCLC treatment by becoming, alone or in combination with platinum-based chemotherapy, a mainstay of first-line therapy for advanced NSCLC. This increasingly dictates the identification of predictive biomarkers of response that can guide patient selection, in order to rationalize and personalize therapies, particularly in elderly patients. Immunotherapy in these patients raises questions of efficacy and tolerability related to aging, which is accompanied by a progressive decline in various body functions. Physical, biological and psychological changes contribute to individual validity status and, preferably, ‘fit’ patients are generally enrolled in clinical trials. In elderly patients, especially frail and complex patients with more than one chronic disease, data are poor and specific prospective studies are needed. This review reports the main available results on the use of immune checkpoint inhibitors in older patients with advanced NSCLC, in terms of efficacy and toxicity, and aims to highlight the need to better predict which patients might benefit from immunotherapy agents by probing knowledge and integrating information on immune system changes and age-related physiopathological modifications. MDPI 2023-04-15 /pmc/articles/PMC10136482/ /pubmed/37190247 http://dx.doi.org/10.3390/cancers15082319 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Spagnuolo, Alessia
Gridelli, Cesare
The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
title The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
title_full The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
title_fullStr The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
title_full_unstemmed The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
title_short The Role of Immunotherapy in the First-Line Treatment of Elderly Advanced Non-Small Cell Lung Cancer
title_sort role of immunotherapy in the first-line treatment of elderly advanced non-small cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136482/
https://www.ncbi.nlm.nih.gov/pubmed/37190247
http://dx.doi.org/10.3390/cancers15082319
work_keys_str_mv AT spagnuoloalessia theroleofimmunotherapyinthefirstlinetreatmentofelderlyadvancednonsmallcelllungcancer
AT gridellicesare theroleofimmunotherapyinthefirstlinetreatmentofelderlyadvancednonsmallcelllungcancer
AT spagnuoloalessia roleofimmunotherapyinthefirstlinetreatmentofelderlyadvancednonsmallcelllungcancer
AT gridellicesare roleofimmunotherapyinthefirstlinetreatmentofelderlyadvancednonsmallcelllungcancer